Literature DB >> 8723486

Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.

S Palmer1, J Harmenberg, S Cox.   

Abstract

The combinations of foscarnet plus 2',3'-dideoxyinosine and foscarnet plus 2',3'-dideoxycytidine synergistically inhibit the replication of human immunodeficiency virus type 1 isolates, including two 3'-azido-3'-deoxythymidine-resistant isolates. The combination of 2',3'-dideoxyinosine plus 2',3'-dideoxycytidine showed additive inhibition of the majority of the human immunodeficiency virus isolates tested. All three combinations showed pronounced antagonistic cytotoxicity and thus were less toxic to the growth of peripheral blood mononuclear cells than the separate drugs.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8723486      PMCID： PMC163311          DOI： 10.1128/AAC.40.5.1285

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  29 in total

Review 1.  HIV drug resistance.

Authors:  D D Richman
Journal:  AIDS Res Hum Retroviruses       Date:  1992-06       Impact factor: 2.205

2.  Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS.

Authors:  S Land; G Terloar; D McPhee; C Birch; R Doherty; D Cooper; I Gust
Journal:  J Infect Dis       Date:  1990-02       Impact factor: 5.226

3.  Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.

Authors:  X B Kong; Q Y Zhu; R M Ruprecht; K A Watanabe; J M Zeidler; J W Gold; B Polsky; D Armstrong; T C Chou
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

4.  Dynamic changes in HIV-1 quasispecies from azidothymidine (AZT)-treated patients.

Authors:  J Wahlberg; J Albert; J Lundeberg; S Cox; B Wahren; M Uhlén
Journal:  FASEB J       Date:  1992-07       Impact factor: 5.191

5.  Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers.

Authors:  J Albert; E M Fenyö
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

6.  Synergistic inhibition of human immunodeficiency virus replication in vitro by combinations of 3'-azido-3'-deoxythymidine and 3'-fluoro-3'-deoxythymidine.

Authors:  J Harmenberg; A Akesson-Johansson; L Vrang; S Cox
Journal:  AIDS Res Hum Retroviruses       Date:  1990-10       Impact factor: 2.205

7.  A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.

Authors:  A G Palestine; M A Polis; M D De Smet; B F Baird; J Falloon; J A Kovacs; R T Davey; J J Zurlo; K M Zunich; M Davis
Journal:  Ann Intern Med       Date:  1991-11-01       Impact factor: 25.391

Review 8.  Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.

Authors:  D Faulds; R N Brogden
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

9.  Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy.

Authors:  C A Boucher; M Tersmette; J M Lange; P Kellam; R E de Goede; J W Mulder; G Darby; J Goudsmit; B A Larder
Journal:  Lancet       Date:  1990-09-08       Impact factor: 79.321

10.  Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics.

Authors:  V A Sundqvist; J Albert; E Ohlsson; J Hinkula; E M Fenyö; B Wahren
Journal:  J Med Virol       Date:  1989-11       Impact factor: 2.327
View more
  3 in total

Review 1.  Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.

Authors:  J C Adkins; D H Peters; D Faulds
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

2.  Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.

Authors:  S Palmer; R W Shafer; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

3.  Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development.

Authors:  S Palmer; R W Shafer; T C Merigan
Journal:  AIDS       Date:  1999-04-16       Impact factor: 4.177
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.